Maxacalcitol

Maxacalcitol
Clinical data
Trade namesOxarol
Other names22-Oxacalcitriol; OCT
Routes of
administration		IV or topical
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • (1R,3S,5Z)-5-[(2E)-2-[(1S,3aS,7aS)-1-[(1S)-1-(3-Hydroxy-3-methylbutoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.212.050
Chemical and physical data
FormulaC26H42O4
Molar mass418.618 g·mol−1
3D model (JSmol)
  • C[C@@H]([C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C)OCCC(C)(C)O
  • InChI=1S/C26H42O4/c1-17-20(15-21(27)16-24(17)28)9-8-19-7-6-12-26(5)22(10-11-23(19)26)18(2)30-14-13-25(3,4)29/h8-9,18,21-24,27-29H,1,6-7,10-16H2,2-5H3/b19-8+,20-9-/t18-,21+,22+,23-,24-,26+/m0/s1
  • Key:DTXXSJZBSTYZKE-ZDQKKZTESA-N

Maxacalcitol (trade name Oxarol) is a vitamin D3 analog and vitamin D receptor activator (VDRA).[1] As a pharmaceutical drug, it is used as an injection to treat secondary hyperparathyroidism resulting from hemodialysis and as a topical ointment for psoriasis.[2]

It was approved for use in Japan in 2010[3] and in Taiwan in 2018.[4]

References

  1. ^ Mizobuchi M, Ogata H (March 2014). "Clinical uses of 22-oxacalcitriol". Current Vascular Pharmacology. 12 (2): 324–328. doi:10.2174/15701611113119990023. PMID 23713875.
  2. ^ "Maxacalcitol". Inxight Drugs. National Center for Advancing Translational Sciences, U.S. National Institutes of Health.
  3. ^ "Maxacalcitol". New Drug Approvals in Japan. Kyoto Encyclopedia of Genes and Genomes. D01098.
  4. ^ Fukazawa-Shinotsuka M, Saito T, Abe M, Iida S, Wang IT, Terao K, et al. (January 2022). "Maxacalcitol Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis". Drug Research. 72 (1): 23–33. doi:10.1055/a-1581-7609. PMID 34488237.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.